Healthcare provider profile · identity verified

John M Saran, MD

Internal Medicine · NAPERVILLE, IL · NPI 1720075849

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	327	88
Levothyroxine Sodium	Levothyroxine Sodium	283	78
Atorvastatin Calcium	Atorvastatin Calcium	156	46
Metoprolol Succinate	Metoprolol Succinate	149	39
Losartan Potassium	Losartan Potassium	125	43
Ezetimibe	Ezetimibe	116	32
Amlodipine Besylate	Amlodipine Besylate	115	38
Metformin Hcl	Metformin Hcl	91	40
Furosemide	Furosemide	68	33
Pantoprazole Sodium	Pantoprazole Sodium	66	23
Tamsulosin Hcl	Tamsulosin Hcl	66	22
Methylprednisolone	Methylprednisolone	65	43
Sertraline Hcl	Sertraline Hcl	65	11
Olmesartan Medoxomil	Olmesartan Medoxomil	63	18
Allopurinol	Allopurinol	62	21
Gabapentin	Gabapentin	62	21
Memantine Hcl	Memantine Hcl	62	suppressed
Amoxicillin	Amoxicillin	57	43
Acetaminophen-Codeine	Acetaminophen With Codeine	54	23
Meloxicam	Meloxicam	54	13
Alprazolam	Alprazolam	53	25
Azithromycin	Azithromycin	52	39
Tizanidine Hcl	Tizanidine Hcl	52	15
Potassium Chloride	Potassium Chloride	51	17
Montelukast Sodium	Montelukast Sodium	50	16
Celecoxib	Celecoxib	46	20
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	43	suppressed
Omeprazole	Omeprazole	42	14
Mounjaro	Tirzepatide	41	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	39	suppressed
Donepezil Hcl	Donepezil Hcl	38	11
Escitalopram Oxalate	Escitalopram Oxalate	38	12
Albuterol Sulfate Hfa	Albuterol Sulfate	37	22
Jardiance	Empagliflozin	37	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	37	16
Cephalexin	Cephalexin	36	25
Tramadol Hcl	Tramadol Hcl	36	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	35	22
Eliquis	Apixaban	35	13
Ozempic	Semaglutide	34	suppressed
Ropinirole Hcl	Ropinirole Hcl	33	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	32	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	30	11
Zolpidem Tartrate	Zolpidem Tartrate	30	12
Pravastatin Sodium	Pravastatin Sodium	28	suppressed
Clopidogrel	Clopidogrel Bisulfate	27	11
Prednisone	Prednisone	27	14
Spironolactone	Spironolactone	27	14
Lorazepam	Lorazepam	26	suppressed
Famotidine	Famotidine	25	suppressed
Finasteride	Finasteride	25	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	25	17
Hydralazine Hcl	Hydralazine Hcl	24	suppressed
Carvedilol	Carvedilol	23	suppressed
Eszopiclone	Eszopiclone	23	suppressed
Levofloxacin	Levofloxacin	23	14
Ondansetron Hcl	Ondansetron Hcl	23	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	23	22
Vitamin D2	Ergocalciferol (Vitamin D2)	23	suppressed
Azelastine Hcl	Azelastine Hcl	22	suppressed
Myrbetriq	Mirabegron	22	suppressed
Torsemide	Torsemide	21	suppressed
Repatha Sureclick	Evolocumab	20	suppressed
Rivastigmine	Rivastigmine	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Warfarin Sodium	Warfarin Sodium	20	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	19	17
Ipratropium Bromide	Ipratropium Bromide	19	suppressed
Levetiracetam	Levetiracetam	19	suppressed
Silodosin	Silodosin	19	suppressed
Synthroid	Levothyroxine Sodium	19	suppressed
Bupropion Hcl	Bupropion Hcl	18	suppressed
Duloxetine Hcl	Duloxetine Hcl	18	suppressed
Lagevrio (Eua)	Molnupiravir	18	18
Xarelto	Rivaroxaban	18	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Repatha Pushtronex	Evolocumab	17	suppressed
Simvastatin	Simvastatin	16	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	15	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	15	suppressed
Citalopram Hbr	Citalopram Hydrobromide	15	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Lisinopril	Lisinopril	15	suppressed
Ondansetron Odt	Ondansetron	15	12
Pregabalin	Pregabalin	15	suppressed
Latanoprost	Latanoprost	14	suppressed
Temazepam	Temazepam	14	suppressed
Trazodone Hcl	Trazodone Hcl	14	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	13	suppressed
Cefdinir	Cefdinir	13	suppressed
Febuxostat	Febuxostat	13	suppressed
Fluticasone Propionate	Fluticasone Propionate	13	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	suppressed
Bumetanide	Bumetanide	12	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	12	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	12	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	12	suppressed
Lubiprostone	Lubiprostone	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Cefadroxil	Cefadroxil	11	suppressed
Dexlansoprazole Dr	Dexlansoprazole	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	11	suppressed
Midodrine Hcl	Midodrine Hcl	11	suppressed
Primidone	Primidone	11	suppressed
Testosterone Cypionate	Testosterone Cypionate	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error